Novoeight® is designed to fit into his world


 

Find your Novo Nordisk Sales Representative

Find your Hemophilia Therapy Sales Manager

Your local HTSM can connect you with tools and information that can help you talk with your patient about how Novoeight® may fit into his world.


 



 

Novoeight® is a treatment for hemophilia A

What is Novoeight®?

Novoeight® is a treatment for hemophilia A that is designed for reliability and precisely engineered for homogeneity.1,2

Novoeight® - a treatment that can keep up with your patient

Why Novoeight®

Your patient doesn't stop, so he needs a treatment that can keep up with him. Novoeight® offers the portability he wants and the bleed control he needs.

Support to help your patient to start with Novoeight®

Getting started

First impressions are lasting ones. Novo Nordisk offers tools and resources to help you support and counsel your patient starting Novoeight®.


References: 1. Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16(2):349-359. 2. Kristensen AK, Kjalke M, Klausen NK, Ezban M, Vad K. Structural comparison of a new recombinant factor VIII molecule, turoctocog alfa, and commercially available FVIII products. Poster presented at: XXIV Congress of the International Society of Thrombosis and Haemostasis (ISTH); June 29-July 4, 2013; Amsterdam, The Netherlands.


 


Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.
 

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.


Please click here for Novoeight® Prescribing Information.